COVID-19 and liver diseases.

Autor: Elghannam MT; Theodor Bilharz Research Institute, Giza, Egypt., Hassanien MH; Theodor Bilharz Research Institute, Giza, Egypt., Ameen YA; Theodor Bilharz Research Institute, Giza, Egypt., ELattar GM; Theodor Bilharz Research Institute, Giza, Egypt., ELRay AA; Theodor Bilharz Research Institute, Giza, Egypt., Turky EA; Theodor Bilharz Research Institute, Giza, Egypt., ELTalkawy MD; Theodor Bilharz Research Institute, Giza, Egypt.
Jazyk: angličtina
Zdroj: Egyptian liver journal [Egypt Liver J] 2022; Vol. 12 (1), pp. 43. Date of Electronic Publication: 2022 Jul 21.
DOI: 10.1186/s43066-022-00202-2
Abstrakt: Coronavirus causes an outbreak of viral pneumonia that spread throughout the world. Liver injury is becoming more widely recognized as a component of the clinical picture of COVID-19 infection. Hepatitis with serum ALT elevation has been reported in up to half of patients. Patients with CLD were at a higher risk of decompensation with liver failure, hospitalization, and mortality. The percentage of acute liver injury (ALI) varied from 5 to 28%. COVID-19 hinders HCV elimination by 2030. It is recommended to continue treatment of chronic HCV and chronic HBV if already receiving treatment. Consider using antiviral therapy to prevent viral flare-ups in patients with occult or resolved HBV and COVID-19 who are receiving immunosuppressive agents. Patients with AIH do not have an increased risk of adverse outcomes even in high-risk areas. There is an association between MAFLD and disease progression. Patients with any type of cancer are at a higher risk of infection and are more likely to develop more severe clinical outcomes. Most societies advise against immunosuppressant modifications in patients with mild COVID-19, whereas in rare cases such as severe lymphopenia, worsening pneumonia, or bacterial or fungal superinfection, reduction or discontinuation of antiproliferative agents and lymphocyte-depleting therapies has been suggested.
Competing Interests: Competing interestsThe authors declare that they have no competing interests.
(© The Author(s) 2022.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje